Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ziquan Zhao, Ruitian Dong, Keni Cui, Qidong You & Zhengyu Jiang. (2023) An updated patent review of Nrf2 activators (2020-present). Expert Opinion on Therapeutic Patents 33:1, pages 29-49.
Read now
Read now
Articles from other publishers (3)
Akira Uruno & Masayuki Yamamoto. (2023) The KEAP1-NRF2 System and Neurodegenerative Diseases. Antioxidants & Redox Signaling 38:13-15, pages 974-988.
Crossref
Crossref
Pedro Henrique Villar-Delfino, Nathália Augusta Oliveira Gomes, Paulo Pereira Christo, José Augusto Nogueira-Machado & Caroline Maria Oliveira Volpe. (2022) Edaravone Inhibits the Production of Reactive Oxygen Species in Phagocytosis- and PKC-Stimulated Granulocytes from Multiple Sclerosis Patients Edaravone Modulate Oxidative Stress in Multiple Sclerosis. Journal of Central Nervous System Disease 14, pages 117957352210925.
Crossref
Crossref
Stephanie Kourakis, Cara A. Timpani, Judy B. de Haan, Nuri Gueven, Dirk Fischer & Emma Rybalka. (2020) Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. Pharmaceuticals 13:10, pages 306.
Crossref
Crossref